(NASDAQ: KZR) Kezar Life Sciences's forecast annual revenue growth rate of 47.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Kezar Life Sciences's revenue in 2024 is $7,000,000.On average, 1 Wall Street analysts forecast KZR's revenue for 2024 to be $873,616,308, with the lowest KZR revenue forecast at $873,616,308, and the highest KZR revenue forecast at $873,616,308. On average, 1 Wall Street analysts forecast KZR's revenue for 2025 to be $1,456,027,180, with the lowest KZR revenue forecast at $1,456,027,180, and the highest KZR revenue forecast at $1,456,027,180.
In 2027, KZR is forecast to generate $674,868,598 in revenue, with the lowest revenue forecast at $674,868,598 and the highest revenue forecast at $674,868,598.